Affymax to Highlight Hematide Data at the American Society of Nephrology Renal Week 2009
* Reuters is not responsible for the content in this press release.
http://www.businesswire.com/news/home/20091022005386/en
Company Webcast on October 30th at 7:00 a.m. PT Features Physician Panel
PALO ALTO, Calif.--(Business Wire)--
Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the
American Society of Nephrology (ASN) Renal Week 2009 taking place October 27
through November 1 in San Diego.
Affymax`s drug, Hematide, is currently in development with Takeda Pharmaceutical
Company Limited for the treatment of anemia associated with chronic renal
failure. Affymax and investigators will make multiple presentations highlighting
Hematide preclinical and clinical data in various treatment settings. These
include preliminary results of a Phase 2 trial in hemodialysis (HD) patients who
are not on an erythropoiesis stimulating agent (ESA), and interim results from
an ongoing Phase 2 study in patients with antibody-mediated pure red cell
aplasia (Ab+PRCA).
Details of Hematide presentations at ASN are as follows:
*Note: All times are listed in Pacific Time
Friday, October 30:
-- Poster session: Preliminary Analysis of Once-Monthly Hematide Efficacy and Safety in HD Patients Not on ESA Treatment
Abstract F-PO1094: 10:00 AM - 12:00 PM
-- Poster session: Efficacy and Safety of Hematide in Patients with Anti-Erythropoietin (EPO) Antibody-Mediated Pure Red Cell Aplasia (Ab+PRCA)
Abstract F-PO1099: 10:00 AM - 12:00 PM
Saturday, October 31:
-- Poster session: Hematide Demonstrates Prolonged In Vitro Binding to the Human Erythropoietin Receptor
Abstract SA-PO2430: 10:00 AM - 12:00 PM
-- Poster session: Hematide Stimulates Similar Signaling Pathways to EPO in UT-7/EPO Cells, but with Different Kinetics and Relative Potency
Abstract SA-PO2431: 10:00 AM - 12:00 PM
-- Poster session: Hematide Is Minimally Immunogenic in Nonclinical Studies
Abstract SA-PO2432: 10:00 AM - 12:00 PM
Company Webcast
Affymax will host an investor webcast with Dr. Richard Lafayette, clinical chief
of nephrology and associate professor of medicine at Stanford University Medical
Center, and Dr. Iain MacDougall, nephrology consultant at the Department of
Renal Medicine, King`s College Hospital. Dr. Lafayette will provide background
on managing anemia in patients with chronic kidney disease. Dr. MacDougall will
discuss pure red cell aplasia (PRCA) a rare, serious and debilitating autoimmune
disorder, which can occur when the body produces neutralizing antibodies to the
currently marketed recombinant human erythropoietins.
The webcast will take place on Friday, October 30th from 7:00-8:00 a.m. PT, and
may be accessed from the investors section of the company's website at
www.affymax.com. A replay will also be available for 30 days following the
presentation.
About Hematide
Hematide is a novel synthetic, PEGylated peptidic compound that binds to and
activates the erythropoietin receptor and thus acts as an erythropoiesis
stimulating agent (ESA).
Affymax and Takeda are collaborating on the development of Hematide and plan to
co-commercialize the product once approved in the United States. The product,
upon approval, will be commercialized in the European Union by Takeda. Phase 3
clinical trials are being conduced to investigate the potential for Hematide to
treat anemia associated with chronic renal disease.
About Anemia in Chronic Renal Failure (CRF)
Anemia in CRF affects many individuals with Chronic Kidney Disease (CKD).
According to the National Kidney Foundation, 26 million Americans - 1 in 9 U.S.
adults - have CKD. Anemia develops in the early stages of CKD and worsens as
patients progress towards total kidney failure and need a dialysis machine to
eliminate waste and water from their blood. In severe or prolonged cases of
anemia, the lack of oxygen in the blood can cause serious and sometimes fatal
damage to the heart and other organs. Benefits of anemia correction in patients
with CKD include decreased morbidity, hospitalization, and mortality.1
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs
to improve the treatment of serious and often life-threatening conditions. For
additional information, please visit www.affymax.com.
Affymax, Inc.
Sylvia Wheeler, 650-812-8861
Executive Director, Corporate Communications
Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters